The Filing Desk

Femasys vs Lucid Diagnostics

Femasys FEMY · Lucid Diagnostics LUCD · Health Care Equipment

Lucid Diagnostics reported revenue of $5 million in fiscal 2025, 2.0 times Femasys' $2 million in fiscal 2025. Femasys' revenue grew 40.8% in its latest year, and Lucid Diagnostics' grew 8.3%. Femasys had an operating margin of -767.0%, against -1054.8% at Lucid Diagnostics. Free cash flow was −$19 million at Femasys and −$47 million at Lucid Diagnostics.

Side by side

FemasysLucid Diagnostics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$5M
Revenue growth40.8%8.3%
Revenue growth a year, last 5 years18.1%—
Gross margin62.0%−41.7%
Operating margin−767.0%−1,054.8%
Net margin−812.3%−1,232.7%
Free cash flow−$19M−$47M
Free cash flow margin−837.9%−992.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count77.6%101.8%
Last close$1.26$0.39
P/E at the last close——
Insider trades, last 12 monthsbought $74,000, sold $0bought $245,000, sold $0
Piotroski F-score2 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
FemasysLucid Diagnostics
Operating margin
Percent of revenue
FemasysLucid Diagnostics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
FemasysLucid Diagnostics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Femasys and Lucid Diagnostics pages.